GSTP1 and neoplasm: For instance, trial NCT03819387, a Phase I study for non-small cell lung cancer (NSCLC), employs lipid nanoparticles (LNPs) to deliver siRNA targeting glutathione S-transferase P (GSTP) with the goal of inhibiting tumor growth in KRAS-mutated cancers.